Previsión

No hay datos de analistas disponibles para esta empresa.

Noticias Ir al feed de noticias

Photocure increases currency-adjusted product revenue by 18% in Q1 2026

Photocure reports currency-adjusted product revenue growth of 18% for Q1 2026 and total revenue of NOK 264.6 million, significantly beating analyst estimates. Drivers were accelerated adoption of blue-light cystoscopy (BLC) in North America (26%) and Europe (11%) as well as milestone payments from partner Asieris. Adjusted EBITDA improved to NOK 15.3 million (Marche 11%), but reported EPS was -0.01 and missed expectations. Photocure confirms its 2026 guidance with expected currency-adjusted product revenue growth of 7–11% and further expansion of its market position for BLC. » Más en de.investing.com
Photocure exceeds sales expectations in Q2 2025 and shares rise sharply

Photocure surpassed forecasts in the second quarter of 2025 with revenue of NOK 135.6 million, achieving 11% growth. The company reported positive EBITDA and a 12.01% increase in its share price, driven by strong results in North America and Europe as well as innovative product developments. Management confirmed its growth outlook and emphasized a strategic focus on expansion and partnerships. » Más en de.investing.com
Photocure achieves record revenue in the second quarter of 2025 and focuses on strategic expansion

Photocure reported record revenue of NOK 135.6 million in the second quarter of 2025, representing 11% growth year-on-year. The company benefited from strong performance in North America and Europe, improved operational efficiency, and strategic partnerships and expansions, particularly in the US, Europe, and China. Photocure confirmed its 2025 outlook and believes it is well positioned for further growth through investments and innovation. » Más en de.investing.com

Dividendos históricos Dividendos

Todas las métricas de dividendos Todas las métricas

En 2013, PhotoCure ya ha pagado 0,26€ en dividendos. El último pago fue en junio 2013.

Datos financieros de la empresa

En el último trimestre, PhotoCure tuvo unos ingresos de 12,59M€ y un beneficio neto de −62,66k€

(EUR)	jun 2026	YoY
Ingresos	+12,59M	10,35%
Beneficio bruto	+11,02M	4,32%
Beneficio neto	−62,66k	115,31%
EBITDA	+4,04M	224,91%

Datos fundamentales

Métrica	Valor
Capitalización bursátil	+132,55M€
Número de acciones	26,76M
Máximo/mínimo de 52 semanas	+6,62€ - +3,76€
Dividendos	No
Beta	0,35
Ratio P/E	+18,96
Ratio PEG	0,00
Ratio P/B	+2,49
Ratio P/S	+2,20

Perfil de la empresa

Photocure ASA, ein pharmazeutisches Spezialunternehmen, ist in der Forschung, Entwicklung, Produktion, Verteilung, Vermarktung und dem Verkauf von pharmazeutischen Produkten in den nordischen Ländern, Deutschland, Frankreich, Österreich, dem Vereinigten Königreich, den Niederlanden, Italien, anderen europäischen Ländern und den Vereinigten Staaten tätig. Das Unternehmen bietet Hexvix/Cysview für die Erkennung und Behandlung von Blasenkrebs an. Außerdem entwickelt es Cevira für die Behandlung von Infektionen mit dem humanen Papillomavirus und von Präkanzerosen des Gebärmutterhalses. Das Unternehmen vertreibt seine Produkte über Lizenzpartner an Pharmagroßhändler, Apotheken und Krankenhäuser. Photocure ASA wurde 1993 gegründet und hat seinen Hauptsitz in Oslo, Norwegen.